We did not discover any other gene mutant had impact for DFS or OS on stage II-III colon cancer patients treated with 5-FU/oxaliplatin-based standard chemotherapy, KRAS tumor mutation status has no major prognostic value for survival was consistent with a previous analysis in a large cohort, though BRAF mutations achieved significance for OS in their study11. This evidence concerns the gene KRAS and neoplasm.